T
MRTX

TOBAM’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

TOBAM’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-112,901
Closed -$7.88M – 455
2022
Q3 		$7.88M Buy
112,901
+63,164
+127% +$4.67M 0.55% 56
2022
Q2 		$3.34M Buy
+49,737
New +$3.16M 0.21% 84
2021
Q2 		– Sell
-160
Closed -$27K – 450
2021
Q1 		$27K Hold
160
– – ﹤0.01% 420
2020
Q4 		$35K Buy
+160
New +$34.6K ﹤0.01% 388

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

TOBAM's MRTX Position: Q4 2022 in Review

TOBAM sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 112,901 shares — an estimated $7.88M sold.

TOBAM first reported a position in MRTX in Q4 2020 and held it in 4 quarters. The position peaked at $7.88M in Q3 2022. 232 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

  • TOBAM reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • TOBAM sold 112,901 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $7.88M.
  • TOBAM first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • TOBAM's Mirati Therapeutics, Inc. Common Stock position peaked at $7.88M in Q3 2022.
  • 232 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on TOBAM's 13F filing for Q4 2022, filed 2 Feb 2023.